Compare IRTC & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | DLB |
|---|---|---|
| Founded | 2006 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | 2016 | 2005 |
| Metric | IRTC | DLB |
|---|---|---|
| Price | $166.88 | $62.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $217.31 | $93.60 |
| AVG Volume (30 Days) | ★ 627.4K | 609.4K |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.62 |
| Revenue | $702,573,000.00 | ★ $1,349,130,000.00 |
| Revenue This Year | $27.30 | $5.03 |
| Revenue Next Year | $17.01 | $4.02 |
| P/E Ratio | ★ N/A | $23.85 |
| Revenue Growth | ★ 25.45 | 5.92 |
| 52 Week Low | $92.52 | $62.41 |
| 52 Week High | $212.00 | $89.66 |
| Indicator | IRTC | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 32.08 |
| Support Level | $149.85 | $63.11 |
| Resistance Level | $174.36 | $64.17 |
| Average True Range (ATR) | 8.37 | 1.13 |
| MACD | -1.55 | -0.14 |
| Stochastic Oscillator | 43.03 | 2.54 |
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.